"The Champagne should probably be kept on ice, at least until the two presidents put pen to paper," said state-owned media China Daily.Traderead more
U.S. stock index futures turned lower after China said it needed to have further discussions before it would sign off on the so-called phase one trade deal President Trump...US Marketsread more
Analysts say the partial U.S.-China trade deal doesn't touch on thorny issues plaguing both sides, and warn talks could break down again.World Economyread more
Economists polled by Reuters had expected Chinese exports denominated in the U.S. dollar to fall by 3% and imports to decline by 5.2% in September, compared to a year ago.China Economyread more
Economists Abhijit Banerjee, Esther Duflo and Michael Kremer won the 2019 Nobel Economics Prize for their work in fighting global poverty, the Royal Swedish Academy of...World Newsread more
Boeing's board removed CEO Dennis Muilenburg as chairman amid the fall out of two 737 Max crashes that killed 346 people.Aerospace & Defenseread more
The U.K. and EU are gearing up for what could be the busiest week in British politics since June 2016.Europe Politicsread more
The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
"It seems like what the two leaders have done is try to set some of the thorny political issues to the side," said Dhruva Jaishankar, director of the U.S. Initiative at the...Asia Politicsread more
Beijing will be opening up its financial industry to foreign ownership from January, namely in the areas of futures, mutual funds and securities.China Economyread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
Believe it or not, the "fumble" of the new health-care law has winners—and they're all publicly traded health-care companies.
The rough rollout of the Affordable Care Act, euphemistically referred to as Obamacare, has President Barack Obama on the political ropes. However, health-care stocks are surging, even in the ensuing confusion of Obama's press conference on Thursday, in which he moved to stanch the bleeding in the individual health-care plan market. Amid the chaos, millions face the prospect of being forced off their insurance plans.
Apparently, investors don't see the current morass as problematic at all. In fact, the thicket of mandates favor the industry by effectively boosting both private and public spending on health care, sector analysts say.
(Read more: 'Obamacare Rally'? It's as good a reason as any)
"The two big long-term drivers ... are Medicaid, which is about to surge, and Medicare Advantage," Phil Seligman an equity analyst at S&P Capital IQ, said in an interview. "For many of these companies, these [programs] are becoming a growing part of their business, and they are prepared for it with medical cost control."
Of those who have successfully enrolled in Obamacare, early returns suggest the vast majority have enrolled in expanded Medicaid. This is because the Affordable Care Act required states to expand the health program for the poor to everyone earning less than a certain amount.
Data released this week showed feeble enrollment rates through HealthCare.gov and the corresponding state-run exchanges. However, Seligman says those figures may be deceptive. In research this week, he noted there were nearly 850,000 completed applications for both individuals and families.
"The numbers appear respectable to us in view of the federal exchange technical issues, and we think the number would have been much greater if the tech problems did not arise," Seligman wrote, adding that the litany of woes dogging Obamacare won't spill over into stocks.
In spite of the pandemonium surrounding the barely functional HealthCare.gov website and the scare headlines of mass cancellations of health plans, bellwether health-care stocks such as Aetna, Cigna, UnitedHealth and Gilead are all trading within shouting distance of 52-week highs. Since Obamacare was enacted in 2010, Gilead is up nearly 200 percent, with Biogen surging more than 300 percent and Amgen up over 90 percent. So what gives?
"Insurers by and large are getting new customers," said Michael Tanner, a health policy analyst at libertarian think-tank the Cato Institute. "The trade-off was always accepting new regulation, in exchange for new mandates and customers."
Insurers have reacted warily to President Obama's remedy for the chaos. Tanner, however, believes the genie can't be put back into the bottle since the law—which is still unlikely to be repealed—mandates that individuals buy insurance, and businesses of a certain size must provide it.
"Customers aren't doing well but the insurers are doing great." Tanner said. "If everybody had to get kicked off the Chevrolet Nova and had to buy a Corvette, it would be good for Chevrolet but not" for car buyers, he said.
—By CNBC's Javier E. David.